| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2020: ¥200,000 (Direct Cost: ¥200,000)
Fiscal Year 2019: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2018: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Outline of Annual Research Achievements |
Dr. Robbe has engaged with exploring the function of the genome in cancer focusing on the non-protein-coding regions, which have been considered less important. She focused on the regulatory elements, promoters and enhancers, in liver cancer, capitalizing on the expertise of colleagues at RIKEN, in particular Dr. Hidewaki Nakagawa’s team. They conducted a broad computational analysis and identified regions involved in liver cancer. We broadened the search of regulatory elements beyond transposons, which was in the original plan, and refocused on a disease for which data became available, slight changes necessary for the success of the project.
She used data collected in my laboratory in a project, Modhep (modelling hepatocellular carcinoma), constituted by Cap-Analysis Gene Expression (CAGE) data and mapped further DNA regulatory elements taking advantage of a second dataset, larger but based on a less sensitive technology to detect enhancers, RNA-sequencing. She developed strategies to filter the data and produced, based on their ability to produce RNAs, a map of liver specific enhancers. She further analyzed the relationships of the newly identified regulatory elements and the primary sequence of human cancers from the Cancer Genome Project by Prof. Nakagawa, identifying a list of regulatory elements altered/mutated in cancer.
This broad exploration of the non-coding part of the genome is new in cancer. A manuscript is being prepared and Dr. Robbe will remain in my laboratory after the JSPS fellow. I am sure that this will be successfully published with a high impact.
|
